Piroxicam–clonixin drug–drug cocrystal solvates with enhanced hydration stability
- 20 June 2019
- journal article
- research article
- Published by Royal Society of Chemistry (RSC) in CrystEngComm
- Vol. 21 (28) , 4145-4149
Abstract
Piroxicam and clonixin can form drug–drug crystalline complexes with the help of suitable solvent molecules.Keywords
Funding Information
- China Postdoctoral Science Foundation (2017LH045)
- National Natural Science Foundation of China (21673279)
- Youth Innovation Promotion Association of the Chinese Academy of Sciences (2012242)
This publication has 29 references indexed in Scilit:
- Energy frameworks: insights into interaction anisotropy and the mechanical properties of molecular crystalsChemical Communications, 2014
- 2 : 1 5-Fluorocytosine–acesulfame CAB cocrystal and 1 : 1 5-fluorocytosine–acesulfame salt hydrate with enhanced stability against hydrationCrystEngComm, 2014
- A Solubility Comparison of Neutral and Zwitterionic PolymorphsCrystal Growth & Design, 2014
- Polymorphs, Salts, and Cocrystals: What’s in a Name?Crystal Growth & Design, 2012
- Benefits of cocrystallisation in pharmaceutical materials science: an updateJournal of Pharmacy and Pharmacology, 2010
- Cocrystals of chlorzoxazone with carboxylic acidsCrystEngComm, 2007
- The properties of organic liquids that are relevant to their use as solvating solventsChemical Society Reviews, 1993
- Structure of the anti-inflammatory drug 4-hydroxy-2-methyl-N-2-pyridyl-2H-1λ6,2-benzothiazine-3-carboxamide 1,1-dioxide (piroxicam)Acta Crystallographica Section B: Structural Science, Crystal Engineering and Materials, 1982
- PiroxicamDrugs, 1981
- Potent antiinflammatory N-heterocyclic 3-carboxamides of 4-hydroxy-2-methyl-2H-1,2-benzothiazine 1,1-dioxideJournal of Medicinal Chemistry, 1973